Fulvio Baggi Selected Research

Fulvio Baggi Research Topics

Disease

20	Myasthenia Gravis 06/2022 - 08/2003
9	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 01/2019 - 09/2003
4	Multiple Sclerosis 02/2022 - 04/2004
4	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 02/2008
3	Thymoma (Thymic Carcinoma) 11/2017 - 07/2005
3	Thymus Hyperplasia 08/2009 - 08/2003
2	Disease Progression 01/2019 - 02/2012
2	Inflammation (Inflammations) 12/2016 - 04/2016
2	Neoplasms (Cancer) 01/2012 - 08/2009
2	Fibrosis (Cirrhosis) 06/2006 - 11/2002
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 06/2006 - 11/2002
1	Multiple System Atrophy 12/2021
1	Parkinson Disease (Parkinson's Disease) 12/2021
1	Infections 01/2018
1	Muscle Weakness 01/2017
1	Experimental Arthritis 01/2017
1	Communicable Diseases (Infectious Diseases) 11/2016
1	Epstein-Barr Virus Infections 04/2016
1	Rare Diseases (Rare Disease) 12/2012
1	Glioblastoma (Glioblastoma Multiforme) 01/2012
1	Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome) 09/2008
1	Myositis (Idiopathic Inflammatory Myopathies) 06/2008
1	Cardiotoxicity 02/2008
1	Encephalomyelitis (Myeloencephalitis) 03/2006
1	Neuroinflammatory Diseases 03/2006
1	Hyperplasia 07/2005
1	Muscular Dystrophies (Muscular Dystrophy) 11/2002
1	Encephalitis (Encephalitis, Rasmussen) 10/2002
1	Epilepsy (Aura) 10/2002
1	Generalized Epilepsy 10/2002
1	Seizures (Absence Seizure) 10/2002
1	Status Epilepticus (Complex Partial Status Epilepticus) 10/2002

Drug/Important Bio-Agent (IBA)

10	Cholinergic ReceptorsIBA 01/2017 - 02/2004
8	Proteins (Proteins, Gene)FDA Link 11/2017 - 11/2002
5	AutoantibodiesIBA 10/2017 - 04/2004
4	Immunosuppressive Agents (Immunosuppressants)IBA 02/2022 - 02/2008
4	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018 - 07/2005
4	Peptides (Polypeptides)IBA 02/2008 - 10/2002
3	Messenger RNA (mRNA)IBA 11/2016 - 11/2002
2	VaccinesIBA 02/2022 - 01/2012
2	Immunoglobulin G (IgG)IBA 02/2022 - 09/2008
2	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 02/2008
2	AntigensIBA 01/2017 - 02/2012
2	pixantrone (BBR 2778)IBA 05/2013 - 02/2008
2	Pharmaceutical PreparationsIBA 05/2013 - 10/2002
2	Phosphotransferases (Kinase)IBA 01/2013 - 10/2011
2	CytokinesIBA 09/2008 - 11/2002
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 06/2006 - 11/2002
1	Biomarkers (Surrogate Marker)IBA 06/2022
1	Complement System Proteins (Complement)IBA 06/2022
1	BNT162 VaccineIBA 02/2022
1	SynucleinsIBA 12/2021
1	alpha-SynucleinIBA 12/2021
1	Therapeutic UsesIBA 01/2019
1	Epstein-Barr virus encoded RNA 1IBA 11/2017
1	Small Nuclear RNA (snRNA)IBA 11/2017
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2017
1	LipidsIBA 01/2017
1	Interleukin-10 (Interleukin 10)IBA 01/2017
1	Interleukin-4 (Interleukin 4)IBA 11/2016
1	MicroRNAs (MicroRNA)IBA 11/2016
1	Antiviral Agents (Antivirals)IBA 04/2016
1	Toll-Like Receptor 4IBA 08/2014
1	muskIBA 01/2013
1	Azathioprine (Imuran)FDA LinkGeneric 01/2013
1	thiopurine methyltransferase (thiopurine S-methyltransferase)IBA 01/2013
1	Biological ProductsIBA 12/2012
1	Immunoglobulins (Immunoglobulin)IBA 08/2009
1	KinesinsIBA 06/2008
1	Mitoxantrone (Novantrone)FDA LinkGeneric 02/2008
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 02/2008
1	DystrophinIBA 06/2006
1	Neutralizing AntibodiesIBA 06/2006
1	Erythropoietin FDA Link 03/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2006
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 03/2006
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 08/2003
1	Connective Tissue Growth FactorIBA 11/2002
1	CollagenIBA 11/2002
1	N 30IBA 10/2002
1	AntibodiesIBA 10/2002

Therapy/Procedure

7	Therapeutics 06/2022 - 03/2006
4	Thymectomy 07/2017 - 08/2003
1	Activities of Daily Living (ADL) 11/2017
1	Immunotherapy 01/2012
1	Immunomodulation 06/2006